Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Martindale Pharmaceuticals Ltd, Bampton Road, Romford, Essex, RM3 8UG, United Kingdom
Espranor 2 mg oral lyophilisate.
| Pharmaceutical Form |
|---|
|
Oral lyophilisate. White to off-white circular oral lyophilisate with a diameter of 10.3 mm, debossed with ‘M2’ on one side. |
Each oral lyophilisate contains 2 mg of buprenorphine (as hydrochloride).
Excipient with known effect: Each oral lyophilisate contains 0.50 mg aspartame.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Buprenorphine |
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the ÎŒ (mu) and Îș (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the ÎŒ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence. |
| List of Excipients |
|---|
|
Gelatin |
Unit dose blisters composed of PVC/OPA/Al/OPA/PVC film with Al/PET/paper lidding with 7 × 1 or 28 × 1 oral lyophilisates, in a cardboard carton.
Not all pack sizes may be marketed.
Martindale Pharmaceuticals Ltd, Bampton Road, Romford, Essex, RM3 8UG, United Kingdom
PL 00156/0364
22/06/2015
| Drug | Countries | |
|---|---|---|
| ESPRANOR | Ireland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
